Russia’s Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund on Tuesday announced the development of the Sputnik V vaccine specifically adapted against Delta and Omicron variants of coronavirus.
As per reports, the new version is also addressing the L-452-R mutation in the Omicron BA5 variant which was not present in the BA1 variant.
“The Delta and Omicron-adapted version of Sputnik V is the most promising version of the vaccine specifically adapted to new variants as compared to those tailored against the combination of the original strain and Omicron variant. The Sputnik V vaccine adapted against the Delta and Omicron variants provides for a significant reduction in the viral load in the lungs of animals infected with the Omicron BA5 variant,” the Russian medical research institute said in a statement on Tuesday.
Sputnik V has become the most exported pharmaceutical product in Russian history being one of the safest and most effective vaccines against coronavirus in the world it claims. Currently, Sputnik V has been authorized in 71 countries with a total population of over 4 billion people.